Clinical Trials Logo

Pituitary ACTH Hypersecretion clinical trials

View clinical trials related to Pituitary ACTH Hypersecretion.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04121988 Terminated - Clinical trials for Pituitary ACTH Secreting Adenoma

Diagnostic Yield of Deep Learning Based Denoising MRI in Cushing's Disease

Start date: January 10, 2020
Phase:
Study type: Observational

Negative MRI findings may occur in up to 40% of cases of ACTH producing microadenomas. The aim of the study is to evaluate if detection of ACTH producing microadenomas can be increased using deep learning based denoising MRI.

NCT ID: NCT02160730 Terminated - Cushings Disease Clinical Trials

Treatment of Cushing's Disease With R-roscovitine

Start date: May 2014
Phase: Phase 2
Study type: Interventional

The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease. To date, R-roscovitine has been evaluated in several Phase I and II studies and has shown early signs of anti-cancer activity in approximately 240 patients.

NCT ID: NCT01915303 Terminated - Cushings Disease Clinical Trials

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Start date: March 6, 2014
Phase: Phase 2
Study type: Interventional

The main purpose of this prospective, multicenter, open-label phase II study, was to evaluate the efficacy and safety of pasireotide alone or in combination with cabergoline in patients with Cushing's disease.

NCT ID: NCT00881283 Terminated - Cushing's Disease Clinical Trials

Long-term Cardiovascular Risk in Cured Cushing's Patients

Start date: September 8, 2008
Phase:
Study type: Observational

The purpose of this study is to determine whether subjects who have been affected by Cushing's disease in the past maintain some different characteristics compared with subjects who have never been diagnosed with the disease.

NCT ID: NCT00612066 Terminated - Cushing's Disease Clinical Trials

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Start date: April 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).